Strides

Press Release

October 20, 2018

Strides receives USFDA approval for Gabapentin Capsules

Product to be marketed by Strides Pharma Inc. in the US markets

Bangalore, October 20, 2018 Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for ***Gabapentin Capsules USP, 100 mg, 300 mg, and 400 mg*** from the United States Food & Drug Administration (US FDA). Gabapentin Capsules is a generic version of Neurontin Capsules® of Pfizer Inc. The product received approval in the first cycle of review of 10 months under the GDUFA II regime.

According to IQVIA MAT data, the US market for **Gabapentin Capsules *USP, 100 mg, 300 mg, and 400 mg*** is approximately US$ 270 Mn. The product will be marketed by Strides Pharma Inc. in the US Market.

The company has 78 cumulative ANDA filings with USFDA of which 53 ANDAs have been approved as of date and 25 are pending approval.

About Gabapentin Capsules

Gabapentin is an anticonvulsant or antiepileptic drug used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles in adults.

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is global pharmaceutical Company headquartered in Bangalore. The Company has two business verticals, viz., Regulated Markets and Emerging Markets. The Company has a global manufacturing footprint with 7 manufacturing facilities spread across three continents including 5 facilities for the Regulated Markets and 2 facilities for the Emerging Markets. The Company has strong R&D infrastructure in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company's website at www.strides.com

For further information, please contact:

Strides Badree Komandur, Executive Director - Finance +91 80 6784 0747 **Investor Relations:** Kannan. N: +91 98450 54745 Vikesh Kumar: +91 80 6784 0827 Sandeep Baid : +91 80 6784 0791 **Strides Pharma Science Limited** (Formerly Strides Shasun Limited) CIN : L24230MH1990PLC057062 Regd. Office: 201, 'Devavrata', Sector - 17, Vashi, Navi Mumbai - 400 703 Corp. Office: Strides House, Bannerghatta Road, Bangalore - 560076 Email: investors@strides.com	**PR Consultancy** Fortuna PR K Srinivas Reddy: +91 90005 27213 srinivas@fortunapr.com K Priya: +91 95354 25418 priya@fortunapr.com